Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 7.25%, which has investors questioning if this is right time ...

Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a ...

StockNews.com assumed coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) in a research report sent to investors on Sunday morning. The brokerage issued a sell rating on ...

Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. On average, equities analysts anticipate that Lexicon Pharmaceuticals will post -0.66 EPS ...

THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a presentation at the 24th Annual ...

THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a presentation at the 24th Annual ...

THE WOODLANDS, Texas - Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), a biopharmaceutical company, will be participating in the 24th Annual Needham Virtual Healthcare Conference on April 9.

THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a presentation at the 24th Annual ...

THE WOODLANDS, Texas - Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), a biopharmaceutical company, will be participating in the 24th Annual Needham Virtual Healthcare Conference on April 9. The company ...

Shares of Lexicon Pharmaceuticals LXRX have jumped 30% after signing a licensing deal for its pre-clinical obesity drug LX9851 with pharma giant Novo Nordisk NVO last week. Per the deal terms ...